EUVIMEDEUVIMED entdecken
Crossref

Click Chemistry‐Aided Synthesis of Triazole‐Tethered Benzothiazoles as Novel Multifunctional Agents Against Alzheimer's Disease

Mostafa M Elbadawi iD, Abdullah A Elgazar iD, Ahmed A Hefny iD, Maha-Hamadien Abdulla, Thamer Bin Traiki, Eslam Roshdy iD, Mohammad M Al-Sanea iD, Manabu Abe iD, Wagdy M Eldehna iD, Praveen P N Rao iD, Abdelrahman Hamdi iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Mostafa M Elbadawi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt. Hauptthemen laut MEDLINE: Triazoles, Alzheimer Disease, Benzothiazoles, Cholinesterase Inhibitors. Die Arbeit nennt 90 Literaturangaben. Gefördert von: This study was supported by the King Saud University., King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the current medical era, Alzheimer's disease (AD) stands as a challenging multifaceted neurodegenerative disorder characterized by diverse pathological features that necessitate the development of multi‐target directed ligands (MTDLs) as a promising therapeutic approach. This study reports the design and synthesis of triazole‐tethered benzothiazole derivatives ( 10a–r and 11a–e ) as MTDLs for AD. These molecules have been evaluated for their potential to inhibit cholinesterases, amyloid‐β (Aβ) aggregation, and their reactive oxygen species (ROS) scavenging ability. Benzothiazoles 10f , 10l , and 11c exhibited good inhibition of human acetylcholinesterase ( h AChE) with IC 50 values of 100, 110, and 140 nM, respectively, and were better than tacrine (IC 50 = 160 nM). Furthermore, they inhibited Aβ42 aggregation with percent inhibition of 49.4%, 45.1%, and 39.3%, respectively. It should be emphasized that the most potent h AChE and Aβ42 dual inhibitors, 10f and 10l , displayed efficient antioxidant activities (57.2% and 47.5%, respectively) and were better than resveratrol (40.8%). Noteworthy, the developed molecules were not cytotoxic to mouse hippocampal neuronal cells (HT22) at 25 µM, with cell viability ranging from 79.2% to 113.3%, highlighting their potential to be considered as novel scaffolds for CNS drug development. A molecular docking study proposed that 10f and 10l interacted with both the catalytic and peripheral active sites of h AChE similar to donepezil and displayed favorable binding. Also, the docking study suggested the binding mode of 10f to Aβ40 and Aβ42. These results show that benzothiazoles 10f and 10l are promising candidates for the development of novel MTDLs for the effective management of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesAlzheimer DiseaseBenzothiazolesCholinesterase InhibitorsNeuroprotective AgentsHumansAmyloid beta-PeptidesStructure-Activity RelationshipClick ChemistryMolecular StructureReactive Oxygen SpeciesAcetylcholinesteraseAntioxidantsDose-Response Relationship, DrugAnimalsMolecular Docking SimulationPeptide FragmentsDrug DesignMice

Stichwörter der Autor:innen

acetylcholinesterase inhibitorsamyloid‐βclick chemistrydesignsynthesis

Substanzen

TriazolesBenzothiazolesAmyloid beta-PeptidesCholinesterase InhibitorsReactive Oxygen SpeciesAcetylcholinesteraseAntioxidantsamyloid beta-protein (1-42)Neuroprotective AgentsPeptide Fragments

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
  • Department of Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, Hiroshima, Japan.
  • Department of Pharmacognosy, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
  • School of Pharmacy, Health Sciences Campus, University of Waterloo, Ontario, Waterloo, Canada.
  • Department of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
  • Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

ORCID-Profile: Mostafa M Elbadawi, Abdullah A Elgazar, Ahmed A Hefny, Eslam Roshdy, Mohammad M Al-Sanea, Manabu Abe, Wagdy M Eldehna, Praveen P N Rao, Abdelrahman Hamdi

Förderung

  • This study was supported by the King Saud University.
  • King Khalid University

Zitieren

APA

Elbadawi, M. M., Elgazar, A. A., Hefny, A. A., Abdulla, M. H., Bin Traiki, T., Roshdy, E., Al-Sanea, M. M., Abe, M., Eldehna, W. M., Rao, P. P. N., & Hamdi, A. (2025). Click Chemistry‐Aided Synthesis of Triazole‐Tethered Benzothiazoles as Novel Multifunctional Agents Against Alzheimer's Disease. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70046

Vancouver

Elbadawi MM, Elgazar AA, Hefny AA, Abdulla MH, Bin Traiki T, Roshdy E, et al. Click Chemistry‐Aided Synthesis of Triazole‐Tethered Benzothiazoles as Novel Multifunctional Agents Against Alzheimer's Disease. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70046

BibTeX
@article{Elbadawi2025,
  author = {Elbadawi, Mostafa M and Elgazar, Abdullah A and Hefny, Ahmed A and Abdulla, Maha-Hamadien and Bin Traiki, Thamer and Roshdy, Eslam and Al-Sanea, Mohammad M and Abe, Manabu and Eldehna, Wagdy M and Rao, Praveen P N and Hamdi, Abdelrahman},
  title = {Click Chemistry‐Aided Synthesis of Triazole‐Tethered Benzothiazoles as Novel Multifunctional Agents Against Alzheimer's Disease},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70046}
}
Kostenlos starten →